ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - acid casein 5.8 g / 100 ml; ascorbic acid 77.4 mg / 100 ml - liquid - fat/carbohydrates/proteins/minerals/vitamins, combinations - theraputic nutrition for people with copd (chronic obstructive pulmonary disease). ahigh calorie low carbohydrate formula specifically dasigned to help reduce carbon dioxide producton.

ישראל - עברית - Ministry of Health

i.g.diagnostics - כלל האוכלוסיה - מערכת ניטור עצמי לגלוקוז בדם

ישראל - עברית - Ministry of Health

מדטכניקה בע"מ - צוות טכני - ביצוע משטחי שתן

ישראל - עברית - Ministry of Health

medison pharma ltd - sapropterin dihydrochloride - טבליות מסיסות - sapropterin dihydrochloride 100 mg - sapropterin - sapropterin - kuvan is indicated for the treatment of hyperphenylalaninaemia (hpa) in adult and paediatric patients of 4 years of age and over with phenylketonuria (pku) who have been shown to be responsive to such treatment.kuvan is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adult and paediatric patients with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

ישראל - עברית - Ministry of Health

teva israel ltd - mupirocin - משחה - mupirocin 2 % - mupirocin - mupirocin - acute primary bacterial skin infections susceptible to the drug e.g. impetigo and folliculitis.

ישראל - עברית - Ministry of Health

bayer israel ltd - testosterone undecanoate - תמיסה להזרקה - testosterone undecanoate 250 mg/ml - testosterone - testosterone - testosterone replacement therpay in primary and secondary male hypogonadism.

ישראל - עברית - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - טבליות מצופות פילם - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections: respiratory infections: bronchitis: acute exacerbation of chronic bronchitis ; pneumonia: community acquired ; sinusitis: acute uncomplicated; community-acquired spontaneous and wound infections of the skin and skin structure.

ישראל - עברית - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - טבליות מצופות פילם - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections: respiratory infections: bronchitis: acute exacerbation of chronic bronchitis ; pneumonia: community acquired ; sinusitis: acute uncomplicated; community-acquired spontaneous and wound infections of the skin and skin structure.

ישראל - עברית - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - תמיסה לאינפוזיה - moxifloxacin as hydrochloride 1.6 mg/ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.